Alnylam Business Model Canvas
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Alnylam Bundle
Business Model Canvas: Strategic playbook for a leading RNAi therapeutics innovator
Unlock Alnylam’s strategic playbook with our Business Model Canvas — a concise, actionable breakdown of its value propositions, key partners, and revenue engines. Perfect for investors and strategists seeking competitive insight. Download the full Word/Excel canvas to benchmark, adapt, and execute with confidence.
Partnerships
Academic and Research Institutes
Collaborations with universities and research hospitals expand Alnylam's target discovery and translational science, supporting its portfolio of four approved RNAi therapies as of 2024. Access to clinician-scientists accelerates study design and patient recruitment for late-stage programs. Joint publications increase credibility in RNAi therapeutics, while IP and data-sharing frameworks de-risk early innovation and enable co-development.
Biopharma Strategic Alliances
Alliances with large pharmas provide co-development, co-commercialization and global reach, enabling Alnylam to scale RNAi programs beyond its commercial footprint; Alnylam reported >$1B in product revenue by 2024, underscoring partner-enabled market expansion.
Partners contribute complementary modalities, indication expertise and capital, while structured milestone payments and tiered royalties align incentives across portfolios.
Joint steering committees and governance mechanisms accelerate decision speed and portfolio prioritization, shortening timelines for phase advancement and launch coordination.
Contract Development and Manufacturing Organizations
CMOs supply GMP oligonucleotide synthesis and fill-finish capacity, enabling Alnylam to avoid heavy capital spending on in-house plants. Flexible CMO capacity lowers fixed costs and supports launch scaling, important as the oligonucleotide therapeutics market was estimated at about $6.8 billion in 2024. Robust quality systems ensure regulatory compliance across regions. Redundant CMO networks reduce supply risk for critical RNAi components.
Clinical Trial Networks and CROs
- Operational excellence: centralized project management
- Recruitment: expanded site networks, faster enrollment
- Standardization: central labs/imaging reduce endpoint variance
- Financial impact: compress timelines, lower per-trial spend
Payer and HTA Collaborations
Payer and HTA collaborations guide Alnylam on evidence needed for reimbursement and enable outcomes contracts; as of 2024 Alnylam had 4 marketed RNAi therapies informing these dialogues. Early payer engagement shapes trial endpoints to align with reimbursement needs, while real-world data partnerships validate long-term clinical and economic value. Value-based agreements improve patient access for high-cost therapies by tying payment to outcomes.
- Engagement → endpoints aligned to HTA expectations
- Outcomes contracts reduce payer budget risk
- RWD partnerships validate durability and safety
- VBA models increase uptake of high-cost RNAi drugs
Partnerships speed RNAi commercialization; >$1B revenue 2024
Alnylam's partnerships with academia, pharmas, CMOs, CROs and payers accelerate discovery, scale commercialization and de-risk manufacturing and reimbursement, supporting four approved RNAi therapies and >$1B product revenue in 2024. External CMOs and CROs cut capex and trial timelines; payer/RWD deals enable value-based access.
| Partner | Role | 2024 metric |
|---|---|---|
| Academia | Discovery/translation | 4 approved therapies |
| Pharma | Co-dev/commercial | >$1B revenue |
| CMOs/CROs | Manufacturing/trials | Oligo market $6.8B; CROs $60B |
| Payers | Reimbursement/RWD | Outcomes contracts |
What is included in the product
Detailed Word Document
A comprehensive, pre-written Business Model Canvas for Alnylam Pharmaceuticals detailing customer segments, channels, value propositions, key partners, activities, resources, cost structure, and revenue streams aligned with its RNAi therapeutic strategy. Ideal for presentations and investor discussions, it includes competitive advantages, SWOT-linked insights, and actionable validation using real-world company data.
Customizable Excel Spreadsheet
High-level view of Alnylam’s business model with editable cells, clarifying how RNAi therapeutics, strategic partnerships, and commercialization pathways relieve R&D, regulatory, and market-access pain points. Clean one-page snapshot for teams to align strategy and accelerate decision-making.
Activities
RNAi Drug Discovery
Design and screen siRNAs against validated disease genes using Alnylam’s discovery engine, supporting a pipeline of 20+ preclinical and clinical programs and four approved RNAi medicines as of 2024. Optimize chemistry and liver-targeted GalNAc conjugates for enhanced hepatocyte delivery. Conduct in vitro and in vivo proof-of-concept studies and advance selected candidates into IND-enabling packages.
Clinical Development
Run Phase 1–3 studies across rare and cardio-metabolic indications, establishing dosing, efficacy endpoints and safety profiles through single- and multiple-ascending dose cohorts. Manage global trial operations and site engagement across multinational networks to ensure enrollment and data quality. Prepare integrated summaries of safety and efficacy for regulatory filings (NDA/MAA) and regulatory interactions.
Regulatory and Market Access
Engage regulators early on INDs and through NDAs/MAAs, managing post‑marketing commitments to secure approvals and lifecycle extensions; Alnylam reported 2024 net product revenue of about $2.9B. Align labeling tightly with demonstrated clinical value and safety to support uptake. Build robust HEOR dossiers for HTA review and real‑world evidence generation. Shape pricing, reimbursement and access strategies to maximize patient access and payer uptake.
Manufacturing and Quality
In 2024 Alnylam scaled GMP oligonucleotide production through its CDMO network to support commercial supply of ONPATTRO and GIVLAARI, maintaining rigorous CMC controls, release testing and stability programs while implementing QMS and continuous process verification to reduce batch variability.
- CDMO scale-up for ONPATTRO and GIVLAARI commercial supply
- Robust CMC, release testing, stability programs
- QMS + continuous process verification
- Supply chain redundancy for critical raw materials
Medical Affairs and Pharmacovigilance
Medical Affairs and Pharmacovigilance deliver balanced scientific exchange to HCPs, drive real-world evidence generation (over 40 RWE studies by 2024), monitor safety signals continuously and implement risk mitigation plans, and equip KOLs and centers of excellence with patient-level and outcomes data to inform care and label updates.
- RWE studies: 40+ (2024)
- Safety monitoring: continuous global pharmacovigilance
- KOL support: data grants and centers of excellence
RNAi pipeline: 20+ programs, 4 approvals, $2.9B revenue and 40+ RWE studies
Design/screen siRNAs for 20+ preclinical/clinical programs and four approved RNAi medicines (2024); optimize GalNAc chemistry and advance IND packages. Run global Phase 1–3 trials, prepare NDA/MAA filings and HEOR for access; 2024 net product revenue ~$2.9B. Scale GMP CDMO supply, CMC/QMS controls; conduct 40+ RWE studies and continuous pharmacovigilance.
| Metric | 2024 value |
|---|---|
| Programs | 20+ |
| Approved medicines | 4 |
| Net product revenue | $2.9B |
| RWE studies | 40+ |
Preview Before You Purchase
Business Model Canvas
The document you're previewing is the actual Alnylam Business Model Canvas you’ll receive after purchase; it’s not a mockup or sample. When you complete your order, you’ll get this same professional, ready-to-edit file with all sections included. What you see is what you’ll download—no surprises, just the full deliverable ready for use.
Resources
Proprietary RNAi Platform
Proprietary RNAi platform combines core know-how in siRNA design, chemical modification, and intracellular delivery to optimize potency and durability. GalNAc conjugation enables selective hepatocyte uptake via the ASGPR pathway, underpinning late-stage liver-targeted assets. Screening libraries (>1 million sequences) and bioinformatics pipelines drive target selection, supporting a 20+ program multi-indication pipeline (2024).
Intellectual Property Portfolio
Alnylam’s patent portfolio protecting RNAi chemistries, delivery platforms and targets underpins competitive moats and, as of 2024, supports a commercial franchise of four approved RNAi medicines. Robust freedom-to-operate claims boost negotiation power in deals and M&A. Core manufacturing know-how is retained as trade secrets to safeguard scale-up economics. Active licensing programs expand ecosystem reach and partner revenues.
Clinical and Real-World Data
Alnylam leverages 10+ clinical programs to build robust datasets across genetic and cardio-metabolic diseases, integrating biomarker and surrogate-endpoint frameworks used in regulatory submissions. Longitudinal safety and outcomes evidence supports payer discussions, while centralized data lakes accelerate future program design and adaptive trial planning, enhancing go-to-market and HEOR strategies in 2024.
Specialized Talent
Alnylam's specialized talent spans oligonucleotide chemistry, biology, CMC and regulatory, supported by clinical operations and market access teams that enabled global launches across 60+ countries (2024); the company maintains a pipeline of >20 programs with 6 in late-stage development (2024).
- Experts: oligo chemistry, CMC, regulatory
- Operations: clinical, market access
- Field: MSLs, HEOR specialists
- Leadership: rare-disease launch experience
Partner and Supplier Network
Alnylam relies on trusted CMOs, CROs, and diagnostics collaborators to scale RNAi development and commercial supply, while global distribution partners and specialty pharmacies ensure channel access for rare-disease therapies; technology vendors provide analytics and advanced manufacturing capabilities, and redundant supplier nodes reduce operational risk.
- CMOs/CROs: strategic outsourcing
- Global distributors & specialty pharmacies
- Analytics & manufacturing tech providers
- Redundant nodes mitigate supply risk
RNAi platform drives 20+ programs, 6 late-stage assets and 4 approved medicines
Proprietary RNAi platform and GalNAc delivery underpin 20+ programs and 6 late-stage assets (2024). Patent portfolio and trade-secret CMC support a commercial franchise of 4 approved RNAi medicines. Global launches reached 60+ countries, supported by CMOs/CROs, specialty pharmacies and analytics partnerships.
| Metric | 2024 |
|---|---|
| Approved medicines | 4 |
| Programs | 20+ |
| Late-stage | 6 |
| Countries | 60+ |
Value Propositions
Gene Silencing Precision
Gene silencing directly reduces disease-driving protein expression, with clinical siRNA studies showing >80% knockdown (eg patisiran ~87% TTR reduction in pivotal trials). By targeting upstream mRNA pathways, it enables true disease modification rather than symptomatic relief. Optimized sequence design and chemistry minimize off-target effects and immune activation. The clear, measurable mechanism-of-action supports regulatory review and clinician adoption.
Infrequent Dosing Convenience
Long-acting RNAi enables quarterly or semiannual dosing in many Alnylam programs, reducing treatment burden versus chronic daily regimens and improving adherence and quality of life for patients. Less frequent administration also aligns with specialty clinic workflows, lowering visit frequency and enabling planned infusion schedules that streamline staffing and resource allocation.
Liver-Targeted Delivery
GalNAc conjugation drives ASGPR-mediated hepatocyte uptake, enabling targeted delivery for liver-centric genetic and cardio-metabolic diseases. Real-world GalNAc siRNA products—Alnylam’s vutrisiran (q3M) and Novartis’ inclisiran (q6M)—demonstrate subcutaneous dosing without infusion centers. This platform yields consistent PK/PD and supports scalable, commercial manufacturing.
Robust Clinical and HEOR Evidence
Randomized pivotal trials and long-term extension studies consistently demonstrate durable efficacy and favorable safety profiles for Alnylam therapies, with validated surrogate endpoints linked to clinical outcomes where feasible.
HEOR analyses across indications show measurable cost offsets and strong value propositions to payers, while accumulating real-world evidence since approvals sustains post-approval confidence and uptake.
Pipeline Diversification
Alnylam mitigates single-asset risk by spanning multiple therapeutic areas and, as of 2024, leveraging a reusable RNAi platform that has delivered 5 approved medicines and 20+ clinical-stage programs, accelerating candidate progression while enabling CMC and regulatory synergies and supporting lifecycle management and label-expansion strategies.
- Therapeutic breadth: lowers single-asset exposure
- Platform: speeds discovery/development (5 approvals, 20+ programs in 2024)
- CMC/regulatory: shared processes reduce cost/time
- Lifecycle: label expansions drive long-term value
RNAi: ~87% TTR knockdown; GalNAc q3M–q6M; 5 approvals, 20+ programs
RNAi delivers disease-modifying protein knockdown (patisiran ~87% TTR reduction in pivotal trials), enabling upstream mRNA targeting with optimized chemistry to limit off-target effects. GalNAc-enabled subcutaneous dosing supports q3M–q6M regimens (vutrisiran q3M), lowering treatment burden and aligning with specialty care. Platform delivered 5 approvals and 20+ clinical programs in 2024, with HEOR showing payer value and cost offsets.
| Metric | Value | Evidence |
|---|---|---|
| Approvals/programs (2024) | 5 approvals; 20+ programs | Company pipeline data 2024 |
| Dosing | q3M–q6M | vutrisiran q3M; inclisiran q6M |
| Mechanism efficacy | ~87% TTR knockdown | patisiran pivotal trials |
Customer Relationships
KOL and COE Engagement
Alnylam (NASDAQ: ALNY) leverages advisory boards to shape trial design and practice guidelines, informed by its four approved RNAi therapies as of 2024. Centers of excellence accelerate early adoption through concentrated clinical experience. Ongoing scientific exchange builds clinician trust. Investigator-initiated studies further extend real-world evidence.
Patient Support Services
Alnylam Assist hub services streamline prior authorization and benefits checks to accelerate therapy starts. Co-pay and access programs reduce financial and access barriers for eligible patients. Dedicated nursing support aids onboarding and adherence while tailored educational resources empower patients and caregivers.
Medical Education and MSL Outreach
Non‑promotional medical education targets HCPs across specialties to support appropriate use of RNAi therapies and aligns with Alnylam’s 2024 commercial scale following reported 2024 revenue of $2.05 billion. MSLs deliver deep data, mechanism and safety insights directly to clinicians and key opinion leaders. Congress symposia and peer‑reviewed publications sustain visibility and clinical adoption. Responsive medical information handles real‑time clinical inquiries and safety reports.
Payer and HTA Partnerships
Payer and HTA partnerships use rigorous value dossiers and budget impact models to inform coverage decisions; outcomes-based agreements align price to performance while regular evidence updates preserve formulary status; collaborative real-world evidence studies validate long-term clinical and economic value.
- Value dossiers and budget impact models
- Outcomes-based agreements
- Ongoing evidence updates
- Collaborative RWE studies
Post-Market Safety and RWE
Alnylam maintains proactive pharmacovigilance and risk-management plans, using registries and RWE to capture outcomes and adherence; as of 2024 Alnylam reported global patient registry data supporting safety across its RNAi portfolio with thousands of patient-years of follow-up. Feedback loops from RWE refine clinical use and transparent reporting—included in public safety updates—builds credibility with regulators and prescribers.
- Proactive PV: continuous signal detection
- Registries: thousands patient-years (2024)
- Feedback loops: guideline and label optimization
- Transparency: public safety reports boost trust
Clinician trust, access and RWE support 4 approved RNAi therapies and $2.05B 2024 revenue
Alnylam builds clinician trust via advisory boards, centers of excellence and MSL engagement supporting 4 approved RNAi therapies and reported 2024 revenue of $2.05B. Patient access is enabled through Alnylam Assist, co-pay programs and nursing support to speed starts and adherence. Proactive PV and registries capture thousands patient‑years (2024) to inform payers and outcomes agreements.
| Metric | 2024 |
|---|---|
| Revenue | $2.05B |
| Approved therapies | 4 |
| Registry follow‑up | thousands patient‑years |
Channels
Specialty Sales Force
In 2024, Alnylam’s specialty sales force deploys focused teams to engage hepatologists, cardiologists, neurologists, and geneticists; account-based selling concentrates resources on top referral centers, clinical educators embed in workflows to support complex care pathways, and CRM systems coordinate field activities and patient-tracking to optimize territory coverage and physician engagement.
Specialty Pharmacies and Distributors
Alnylam uses limited-distribution specialty pharmacies and distributors to manage cold chain logistics and benefits coordination for complex RNAi therapies, aligning with a market where specialty drugs represented about 55% of US drug spending in 2023. These networks enable prior authorization workflows and coordinated refills to reduce gaps in therapy and streamline access. Real-time data feeds support adherence monitoring and outcomes tracking, while contracting optimizes payer coverage, reimbursement and logistics.
Hospital and COE Pathways
Formularies and treatment protocols drive adoption and hospital uptake, shaping reimbursement pathways. Onpattro (patisiran) is administered IV every 3 weeks and is typically managed in infusion clinics. Care coordinators streamline prior authorization and scheduling. Outcomes tracking feeds quality programs and real-world evidence supporting coverage; Alnylam reported $1.65B product revenue in 2023.
Digital and Medical Platforms
Alnylam leverages medical portals, webinars and accredited CME to engage HCPs, while disease-awareness sites reach patients; in 2024 Alnylam reported approximately $3.9 billion in revenue, funding expanded digital outreach. Secure HCP portals deliver product resources and case support, and analytics continually refine targeting and content to improve engagement and ROI.
- Medical portals: HCP education/CME
- Webinars: live and on-demand HCP reach
- Disease sites: patient awareness and support
- Secure HCP portals: resources and case tools
- Analytics: audience targeting, content optimization
Global Partner Co-Promotion
Global Partner Co-Promotion leverages ex-US partners to extend reach and localize access strategies, with Alnylam reporting 2024 net product revenue above $2.7 billion supporting broader rollout. Shared field teams amplify footprint and sales velocity across key markets; local market expertise improves reimbursement success and formulary placement. Joint governance ensures consistent messaging, regulatory alignment and KPI-driven coordination.
- Ex-US localization
- Shared field teams
- Improved reimbursement
- Joint governance/KPIs
Specialty sales, care coordinators and limited-distribution pharmacies power RNAi access
Alnylam deploys specialty sales, account-based selling, care coordinators and CRM to engage HCPs and manage complex RNAi logistics; limited-distribution specialty pharmacies handle cold chain, prior auth and adherence monitoring. Global co-promotion extends reach; digital HCP portals, CME and patient sites drive awareness and outcomes generation, supported by ~$3.9B 2024 revenue and $1.65B product revenue in 2023.
| Metric | Value |
|---|---|
| 2024 revenue | $3.9B |
| 2024 net product rev (ex-US) | $2.7B |
| 2023 product revenue | $1.65B |
| Specialty drugs share (US 2023) | ~55% |
Customer Segments
Rare and Genetic Disease Patients
Individuals with rare and genetic diseases (WHO estimates ~300 million people globally) often have high unmet need and benefit from disease-modifying therapies. Caregivers frequently drive adherence and treatment choices, especially for pediatric and neurologic conditions. Patient advocacy groups (thousands worldwide) shape awareness, reimbursement and access. Small populations (US definition <200,000) require tailored support programs.
Specialist Physicians
Hepatologists, cardiologists, neurologists and ophthalmologists comprise Alnylam’s core prescribers, driving uptake of its RNAi therapies aligned with 2024 net product revenue of approximately $3.6 billion. These specialists prioritize robust phase III/real-world data and simple subcutaneous or IV administration to fit clinic workflows. KOLs in academic centers influence community practice formulary adoption, while multidisciplinary teams coordinate diagnostics, genetic testing and chronic care pathways.
Payers and Health Systems
Commercial insurers (about 178 million privately insured in the US per KFF 2023), Medicare (≈65 million beneficiaries in 2024) and ex-US payers (NHS, HAS, etc.) control access and rely on HTA to assess cost-effectiveness and budget impact. NICE commonly references £20,000–£30,000/QALY thresholds; outcomes-based, risk-sharing contracts are expanding to align incentives. Health systems drive formulary placement and care-pathway adoption.
Clinical Research Partners
Clinical research partners — trial sites, CROs and academic centers — enable Alnylam's program delivery by providing patient access and biomarker-driven cohorts; 2024 industry analyses show biomarker-stratified studies shorten timelines by 15–25%. High-quality, fast data is a primary value driver and long-term partnerships cut startup friction and costs.
- Patient access: accelerates enrollment
- Biomarkers: 15–25% faster studies (2024)
- Data quality/speed: critical value driver
- Long-term ties: reduce startup friction
International Markets
Ex-US regulators, health technology assessment bodies and national payers define distinct approval and reimbursement pathways for Alnylam in 2024, creating varying timelines to market across regions. Local key opinion leaders and specialty centers drive clinical uptake and guideline adoption, especially for rare disease indications. Distribution partners adapt cold-chain logistics, import/export compliance and pharmacovigilance to country-specific requirements, while pricing and patient access mechanisms vary widely by market.
- Regulatory/HTA-driven pathways
- Local KOLs and centers of excellence
- Tailored logistics & compliance via partners
- Country-specific pricing & access
Specialty RNA therapies expand access: ~300M rare patients, $3.6B revenue
Alnylam serves patients with rare/genetic diseases, caregivers and advocacy groups, specialty prescribers (hepatology, cardiology, neurology, ophthalmology) and payers/HTA bodies; high unmet need and specialty-driven uptake underpin revenue and access strategies. Clinical research partners and distribution/regulatory partners enable trials, approvals and market entry across regions.
| Segment | Metric | 2024 |
|---|---|---|
| Patients (rare) | Global estimate | ~300M |
| Net product revenue | Alnylam | $3.6B |
| Medicare | Beneficiaries | ≈65M |
| US privately insured | Population | ≈178M |
Cost Structure
R&D and Platform Investment
Alnylam's R&D and platform investment in 2024 sustained ongoing discovery, preclinical studies and target validation across more than 25 programs, supported by an annual R&D run-rate exceeding $1 billion. Significant spend is allocated to bioinformatics and chemistry optimization to refine siRNA chemistries and delivery, while platform enhancements target improved delivery and durability. Lab facilities and specialized equipment comprise a material portion of capital and operating expenditure.
Clinical Trial Expenses
Clinical trial expenses for Alnylam drive major Cost Structure items: site fees, CRO contracts and patient-related costs (travel, stipends) dominate operational spend; Alnylam's R&D outlay exceeded $1 billion in 2024 reflecting this burden. Manufacturing clinical supply and cold-chain logistics add significant incremental costs per study. Biomarkers, imaging and central labs commonly represent material specialized spend, while data management and regulatory documentation require continuous investment to support filings and compliance.
Manufacturing and COGS
Manufacturing and COGS at Alnylam center on GMP oligonucleotide synthesis and fill-finish operations, with quality control, lot release testing and stability programs integrated into per-batch costs. Cold chain logistics and specialized packaging add recurring transport and storage premiums that raise unit COGS. Long-term supplier and capacity reservation commitments create fixed-cost leverage and mitigate supply risk while increasing committed spend.
SG&A and Commercialization
- Sales force
- Marketing & medical education
- Patient support hubs
- Market access & pricing
- Corporate overhead & IT
Milestones, Royalties, and Compliance
Milestones and royalty payments under Alnylams licensing and collaboration agreements drive variable cost exposure, with significant payouts tied to late-stage approvals and commercial launches. Post-marketing commitments and pharmacovigilance operations require ongoing surveillance infrastructure and reporting workflows across jurisdictions. Legal, IP prosecution, and audit activities consume substantial legal fees and contribute to operating expense volatility. Insurance premiums and GMP/quality compliance add recurring fixed costs to support global product supply chains.
2024 revenue $3.17B; R&D run-rate > $1B
Alnylam's 2024 cost base is dominated by R&D/platform investment (annual run-rate exceeding $1 billion) supporting 25+ programs. Clinical trial operations, GMP manufacturing and cold-chain logistics drive major operational spend while SG&A scaled to support launches against FY2024 revenue of $3.17 billion. Milestones/royalties, pharmacovigilance, legal/IP and quality/compliance add ongoing variable and fixed cost exposure.
| Metric | 2024 |
|---|---|
| Revenue | $3.17B |
| R&D run-rate | >$1B |
| Programs | 25+ |
Revenue Streams
Product Sales
Net product sales from Alnylam’s approved RNAi therapies totaled about $2.56 billion in 2024, reflecting uptake across multiple indications. Specialty pharmacy and hospital channels remain primary volume drivers, supporting consistent patient access and infusion-based launches. Geographic expansion into Europe and Asia provided stepwise revenue lifts as new launches and reimbursements rolled out. Pricing stays premium, driven by high unmet need and outcomes-based contracting.
Collaboration Upfronts and Milestones
Payments from strategic alliances are tied to specific R&D and regulatory milestones, providing staggered cash inflows as programs advance. Co-development economics—revenue sharing and milestone splits—diversify cash flow versus sole-product dependency. Option and equity tranches often supplement upfront and milestone cash, preserving runway. Structuring aligns risk-sharing by linking payments to technical and regulatory success.
Royalties and Out-Licensing
Royalties from partners commercializing Alnylam-licensed assets provide recurring revenue, and in 2024 these partner-derived payments continued to supplement product sales. Out-licensing lets Alnylam access external markets without bearing full SG&A, preserving capital efficiency. Milestone and sales-threshold payments add upside while IP licensing monetizes the breadth of Alnylam’s RNAi platform.
Grants and Non-Dilutive Funding
Grants and non-dilutive funding provide government or foundation support for high-need areas, helping Alnylam offset early-stage research costs and validate scientific direction; NIH ecosystem funding reached about 49.7 billion USD in FY2024, underpinning such awards. Regional R&D tax incentives (US simplified credit ~14% of eligible R&D) further reduce net project costs.
- Government grants: NIH FY2024 ~49.7B
- Offsets: reduces early-stage capex
- Validation: de-risks science for investors
- Tax credits: US simplified R&D credit ~14%
Companion and Service Revenues
Companion and service revenues come from diagnostic partnerships and patient services tied to Alnylam therapy use, plus payer-facing RWE and data collaborations; in 2024 Alnylam reported $2.58 billion in total revenue, with these services kept limited but strategic to enable uptake and reimbursement. They enhance ecosystem value and patient retention by linking diagnostics, adherence support, and real-world evidence to product performance.
- Diagnostic partnerships: enable targeted prescribing and market access
- RWE/data services: support payers and reimbursement negotiations
- Strategic scale: limited revenue share but high adoption impact
Product sales $2.56B, total revenue $2.58B 2024
Net product sales $2.56B in 2024; total revenue $2.58B. Alliance payments and milestones provide staged cashflows; royalties and out-licensing add recurring upside. Grants/NIH FY2024 ~49.7B and US R&D credit ~14% reduce net R&D cost. Companion services drive uptake though revenue-limited.
| Revenue Stream | 2024 Value |
|---|---|
| Net product sales | $2.56B |
| Total revenue | $2.58B |
| NIH funding (FY2024) | $49.7B |
| US R&D credit | ~14% |